AlgoTherapeutix appoints Prof Jens Ellrich Chief Medical Officer
8.11.2021 11:00:00 EET | Business Wire | Press release
AlgoTherapeutix (AlgoTx) is a European Biotech developing ATX01, a non-opioid topical treatment for Peripheral Neuropathic Pain.
Stéphane Thiroloix, CEO, comments : “With ATX01 entering Phase II in Chemotherapy-Induced Peripheral Neuropathy and increasing its span of indications, Jens’s medical depth of expertise and biotech experience are a tremendous addition to the team’s profile”.
Jens Ellrich, MD, PhD, spent 18 years in basic and clinical pain research at University hospitals in Germany and Denmark with a track record of more than 85 publications in scientific journals with peer review. He was full professor at RWTH Aachen University and Aalborg University and received the European Award for Pain Research in 2005.
Since 2010, Jens has served as Chief Medical Officer for the international neuroscience start-ups Cerbomed, EBS Technologies, Precisis, Sapiens, and WISE.
Besides his executive roles in the healthcare industry, he serves as adjunct professor of neuroscience at Erlangen University and is a member of the Editorial Advisory Board of the European Journal of Pain. Jens brings a wealth of hands-on experience and expertise in pain research, clinical development, and medical affairs.
About AlgoTherapeutix : AlgoTherapeutix is a French biotech founded in 2018 to develop innovative solutions for complex pain. Its lead program, ATX01, is Phase II ready in painful peripheral neuropathy.
AlgoTherapeutix SAS
49 rue des Nouvelles - 92150 Suresnes
Stéphane Thiroloix - stephane@algotx.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005288/en/
Contact information
Communication : Geneviève Cliquet Consultant – T: +33(0) 607 500 567
contact@cliquet-consultant.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla Agency Launches to Empower Creators Across Entertainment-Based Intellectual Property5.3.2026 17:23:00 EET | Press release
Xsolla, a global video game commerce company, today launched Xsolla Agency, a comprehensive service connecting game developers with premium entertainment-based intellectual property (IP). The integrated offering addresses critical challenges for game creators: access to world-class IP, global monetization capabilities, and the operational infrastructure needed to build sustainable businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305044119/en/ Graphic: Xsolla Xsolla Agency simplifies access to entertainment-based licenses through expert-led negotiations and industry relationships, offering affordable, monetization-focused deals structured for maximum ROI. Strategic IP partnerships increase discoverability, reduce user acquisition costs, and drive higher player spend through impactful LiveOps events and promotional campaigns. The service is backed by the same commerce infrastructure powering 1,500+ game developers
Onego Bio and Sigma Foods Enter Collaboration to Strengthen Egg Protein Innovation and Supply Resilience5.3.2026 17:00:00 EET | Press release
Onego Bio, a food ingredient company producing non-animal egg protein, and Sigma Foods ("SIGMA"), a leading multinational food company, have entered into a collaboration agreement to evaluate the functionality and commercial potential of Bioalbumen®, a non-animal egg protein made with using precision fermentation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305756400/en/ The partnership focuses on advancing ingredient innovation while addressing urgent challenges in today’s egg supply chain—including volatility, rising prices, and avian flu-related disruptions. Bioalbumen® offers a shelf-stable, animal-free alternative that delivers the same functional, nutritional, and sensory performance as traditional eggs, while helping safeguard supply continuity for food manufacturers. Additionally, this collaboration supports Sigma’s commitment to offering safe, nutritious, and high-quality food, while driving science-based inno
Vertex to Present New Data on JOURNAVX ® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures5.3.2026 17:00:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from a Phase 4 study of JOURNAVX® (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults, that demonstrated effective pain management and enabled opioid-free recovery after a broad range of plastic surgical procedures. These data showed that the majority of patients (90.9%) in the study were opioid free through the end of treatment (up to 14 days), demonstrating the potential for JOURNAVX as a core element of opioid-free multimodal treatment for moderate-to-severe acute pain after aesthetic and reconstructive procedures. In contrast, the literature shows opioid-free rates of less than 10% with multimodal treatment without JOURNAVX. These data will be presented at the American Academy of Pain Medicine (AAPM) PainConnect 2026 meeting, March 5-8, 2026, in Salt Lake City, UT. This Phase 4 open-label, multicenter, single-arm study evaluated JOURNAVX w
Andersen Consulting Expands Capabilities Through Collaboration with Opinno5.3.2026 16:30:00 EET | Press release
Andersen Consulting strengthens its platform through a Collaboration Agreement with Opinno, a global consultancy headquartered in Spain that integrates digital transformation with corporate innovation. Founded in 2008, Opinno helps organizations rethink how they innovate, transform, and grow in the digital economy. The firm applies design thinking, agile methodologies, and open collaboration models to deliver results across three core areas: digital transformation, innovation, and content and ecosystems. Its digital transformation practice emphasizes AI from both strategic and design perspectives, while its innovation practice accelerates the development and market launch of products and services. Through its content and ecosystem programs, Opinno drives engagement and helps build connected, future-ready organizations. “At Opinno, innovation and digital transformation are more than processes; they are channels for meaningful impact,” said Pedro Moneo, founder and CEO of Opinno. “Our hy
Ushio Completes Acquisition of OSRAM Entertainment and Industry Business5.3.2026 16:08:00 EET | Press release
Ushio Inc. today announced the successful completion of the acquisition of the OSRAM Entertainment and Industry (ENI) business. As of March 2, 2026, the business officially operates as part of the Ushio Group under the name Ushio INE GmbH (hereinafter: Ushio Industry & Entertainment). This strategic acquisition strengthens Ushio’s global position in specialty lighting and expands its capabilities across entertainment, cinema projection, stage lighting, industrial applications, and high-performance professional solutions. The newly integrated organization combines Ushio’s established technology portfolio and global manufacturing strength with the long-standing expertise, customer relationships, and application knowledge of the former OSRAM Entertainment and Industry team. Marko Haas, General Manager of Business Division of Ushio Industry & Entertainment, commented: “This marks an important milestone for our business and our customers worldwide. By bringing together the experience and tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom